Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196), a leading pharmaceutical company based in China, has announced that it has received approval from the National Medical Products Administration (NMPA) to conduct a clinical study for its drug candidate XS-02 in patients with advanced solid tumors.
XS-02 is a novel oral CHK1 inhibitor that exhibits specific and potent inhibition of the CHK1 physiological function, along with good oral bioavailability. Preclinical studies have demonstrated the drug’s excellent anti-tumor capabilities and a controllable safety profile. Notably, no similar product has been approved for marketing globally, making XS-02 a potentially groundbreaking therapy in the field of oncology.- Flcube.com
